Trigonelline alkaloid is effective in preventing doxorubicin-induced lung damage

被引:1
|
作者
Uslu, Hamit [1 ]
Uslu, Gozde Atila [1 ]
Cicek, Betuel [1 ]
Bolat, Ismail [2 ]
Yildirim, Serkan [2 ]
机构
[1] Erzincan Binali Yildirim Univ, Dept Physiol, Erzincan, Turkiye
[2] Ataturk Univ, Dept Pathol, Erzurum, Turkiye
关键词
Doxorubicin; trigonelline alkaloid; inflammation; apoptosis; NF-kappa B/MAPK; OXIDATIVE STRESS; TOXICITY; RAT;
D O I
10.1080/13813455.2024.2404097
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundOne of the most popular chemotherapy medications is doxorubicin (DOX), however it can have non-negligible damage. When the underlying mechanisms of damage are investigated, the most prominent pathways are oxidative stress, inflammation and apoptosis.AimWe investigated the NF-kappa B/MAPK inflammatory pathway and cellular apoptosis to determine the efficacy of trigonelline alkaloid (TRIG) in preventing DOX-induced lung injury.MethodologyThe study consisted of C, TRIG, DOX and TRIG+DOX groups. TRIG and TRIG+DOX groups received 50 mg/kg TRIG for 7 days. On day 8, DOX and TRIG+DOX groups received a single dose of 15 mg/kg DOX.ResultsOur results showed that apoptosis markers and inflammation were higher in the DOX group. In contrast, TRIG pretreatment partially suppressed apoptosis and decreased inflammation by blocking the activation of the MAPK/NF-kappa B pathway, lowering IL-6 levels, and protecting the lung from apoptotic cell death.ConclusionAssessing TRIG's effectiveness in lung tissue injury, this study may be a crucial first step.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis
    Rigby, Rachael J.
    Carr, Jacquelyn
    Orgel, Kelly
    King, Stephanie L.
    Lund, P. Kay
    Dekaney, Christopher M.
    GUT MICROBES, 2016, 7 (05) : 414 - 423
  • [2] The beneficial role of exercise in preventing doxorubicin-induced cardiotoxicity
    Gaytan, Samantha L.
    Lawan, Ahmed
    Chang, Jongwha
    Nurunnabi, Md
    Bajpeyi, Sudip
    Boyle, Jason B.
    Han, Sung Min
    Min, Kisuk
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [3] Macrophages participate in doxorubicin-induced cardiac damage
    Cerasuolo, Federica Andrea
    Gambardella, Jessica
    Santulli, Gaetano
    Fiordelisi, Antonella
    Wang, Xujun
    Prevete, Nella
    Sommella, Edoardo
    Avvisato, Roberta
    Buonaiuto, Antonietta
    Altobelli, Giovanna Giuseppina
    Ciccarelli, Michele
    Morisco, Carmine
    Sadoshima, Junichi
    Iaccarino, Guido
    Sorriento, Daniela
    VASCULAR PHARMACOLOGY, 2024, 155 : 107309
  • [4] Doxorubicin-induced cardiotoxicity: Are there effective alternatives for prevention?
    Canales, Miguel A.
    MEDICINA CLINICA, 2010, 134 (02): : 70 - 71
  • [5] Betaine Intervention as a Novel Approach to Preventing Doxorubicin-Induced Cardiotoxicity
    Jaiswal, Aiswarya
    Rawat, Pushkar Singh
    Singh, Sumeet Kumar
    Bhatti, Jasvinder Singh
    Khurana, Amit
    Navik, Umashanker
    ADVANCES IN REDOX RESEARCH, 2023, 9
  • [6] An Examination of the Role of Luteolin in Doxorubicin-Induced Testicular Damage
    Elaguel-Tombul, N.
    Sogut, I.
    Kose-Vuruskan, A.
    JOURNAL OF EVOLUTIONARY BIOCHEMISTRY AND PHYSIOLOGY, 2024, 60 (03) : 947 - 956
  • [7] Endogenous PACAP attenuated doxorubicin-induced myocardial damage
    Mori, Hiroyoshi
    Nakamachi, Tomoya
    Ohtaki, Hirokazu
    Hasegawa, Fumio
    Yofu, Sachiko
    Suzuki, Hiroshi
    Takeyama, Youichi
    Shintani, Norihito
    Hashimoto, Hitoshi
    Baba, Akemichi
    Shioda, Seiji
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2010, 42 (03) : 295 - 295
  • [8] MicroRNAs in doxorubicin-induced cardiotoxicity: The DNA damage response
    Kawano, Ippei
    Adamcova, Michaela
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Exercise attenuates doxorubicin-induced skeletal muscle damage
    Smuder, Ashley J.
    Min, Kisuk
    Kavazis, Andreas N.
    FASEB JOURNAL, 2009, 23
  • [10] Effects of Adrenomedullin on Doxorubicin-Induced Cardiac Damage in Mice
    Yoshizawa, Takahiro
    Takizawa, Sho
    Shimada, Shin
    Tokudome, Takeshi
    Shindo, Takayuki
    Matsumoto, Kiyoshi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (05) : 737 - 746